Document Detail


Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.
MedLine Citation:
PMID:  23278640     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and transplant fields. A better understanding of the pathobiology behind the GVHD process has led the way to novel approaches and medications. Here we review the present arsenal of medications used to prevent GVHD, focusing on past experience and the current evidence, and discuss future potential targets.
Authors:
Ron Ram; Rainer Storb
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2013-01-24
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  54     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-07-15     Completed Date:  2014-02-24     Revised Date:  2014-08-05    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  1591-601     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Graft vs Host Disease / drug therapy*,  etiology,  prevention & control
Humans
Immunosuppressive Agents / therapeutic use*
Premedication*
Grant Support
ID/Acronym/Agency:
CA 15704/CA/NCI NIH HHS; CA 18029/CA/NCI NIH HHS; CA 78902/CA/NCI NIH HHS; P01 CA018029/CA/NCI NIH HHS; P01 CA078902/CA/NCI NIH HHS; P30 CA015704/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Multicenter Phase II Trial to Determine the Safety and Efficacy of Combination Therapy With Denile...
Next Document:  Bone Marrow Mast Cell Burden and Serum Tryptase Level as Markers of Response in Patients with System...